Gilead acquires immuno-oncology firm Forty Seven in $4.9 billion deal

pharmafile | March 3, 2020 | News story | Manufacturing and Production, Sales and Marketing Cancer, Forty Seven, Gilead, acquisition, oncology, pharma 

Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share in cash, which brings the total valuation of the latter company to $4.9 billion.

The deal secured unanimous approval from both companies’ Boards of Directors and is expected to close in the second quarter of the year.

The move is seen as a boost to Gilead’s immuno-oncology portfolio, and will include the acquisition of Forty Seven’s lead product, magrolimab, which is currently in development for a range of cancers with unmet need including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). The CD47 inhibitor posted positive Phase 1b data in MDS and AML when combined with azacytidine (Vidaza) back in December last year.

“Magrolimab complements our existing work in haematology, adding a non-cell therapy programme that complements Kite’s pipeline of cell therapies for haematological cancers,” explained Daniel O’Day, Chairman and Chief Executive Officer at Gilead Sciences. “With a profile that lends itself to combination therapies, magrolimab could potentially have transformative benefits for a range of tumour types. We are looking forward to working with the highly experienced team at Forty Seven to help patients with some of the most challenging forms of cancer.”

Dr Mark McCamish, President and Chief Executive Officer at Forty Seven, also said of the deal: “This is an exciting day for patients who may one day benefit from future anti-CD47 therapies and other immuno-oncology treatments based on our research and an exciting time for Forty Seven as this allows us to achieve our vision of helping patients defeat their cancer. We are pleased to join Gilead and believe that by combining our scientific expertise with Gilead’s strength in developing treatments that modify the immune system, we will be able to more rapidly advance our therapies.”

Matt Fellows

Related Content


BioInvent and Transgene announce positive phase 1a solid tumour trial data

Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from …


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

FDA announces acceptance and priority review of NDA for LUMISIGHT imagining agent for breast cancer

Lumicell has announced that the US Food and Drug Administration (FDA) has accepted and granted …

Latest content